|
JPS5916890A
|
|
Xanthine derivative
|
|
FI801875A
|
|
7- (oxoalkyl) -1,3-dialkylxantiner foerfarande foer deras framstaellning och ceiling model innehaollande dessa foereningar
|
|
NZ193654A
|
|
Naphthalene sulphonamido-alkyl-piperidines,pyrrolidines or piperazines and pharmaceutical compositions
|
|
CA1128509A
|
|
Thiotanthine compounds
|
|
NZ193285A
|
|
3-(1,3-dialkylxanthin-7-yl)propan-2-one ketals
|
|
US4256750A
|
|
Pharmaceutical compositions
|
|
IE790811L
|
|
Pharmaceutical compositions containing a xanthine derivative.
|
|
NZ190742A
|
|
Compositions containing 1 3-di-n-butyl-7-(2-ocopropyl)-xanthine for treatment of peripheral vascular disease
|
|
US4225607A
|
|
Pharmaceutical composition containing a xanthine derivative
|
|
YU96177A
|
|
Process for obtaining adenine derivatives
|
|
US4092417A
|
|
Theophylline salts of 5-methylisoxazole-3-carboxylic acid
|
|
JPS5372813A
|
|
Production of 55methyll isooxoll33carboxylic acid and salt thereof
|
|
US4060617A
|
|
Esters of the ophyllinylacetic acid
|
|
JPS5283883A
|
|
Xanthin derivatives and application thereof
|
|
JPS5283851A
|
|
55nnbutyllpyridinee22carboxylic acid derivatives
|
|
CS187326B2
|
|
Method of producing 3-methylpyrazol-5-carboxylates
|
|
HU171387B
|
|
Process for producing new 3-methyl-pyrazolo-5-carboxylates and pharmaceutical compositions containing them as active agent
|
|
GB1426685A
|
|
1,3-bis -beta-ethylhexyl-5 amino-5-methylhexahydropyrimidine- pyridine-3-carboxylate
|
|
US2665235A
|
|
Calcium lactate suppository
|
|
GB346208A
|
|
Improved process for manufacturing dilithium alkali citrates
|
